6533b872fe1ef96bd12d3a4e
RESEARCH PRODUCT
Diabetes and COVID-19: A Tale of 2 Pandemics.
Manfredi RizzoManfredi RizzoWael Al MahmeedAli A. RizviAli A. RizviAndrei Janezsubject
Pharmacology2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)diabetesbusiness.industrySARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19Review Articledapagliflozinmedicine.diseaseVirologyDARE-19Diabetes mellitusPandemicmedicineDiabetes MellitusHumansSGLT2iCardiology and Cardiovascular MedicinebusinessPandemicsHumans Pandemics SARS-CoV-2 COVID-19 Diabetes Mellitusdescription
Abstract: Epidemiological studies indicate that diabetes is the second most common comorbidity in COVID-19 (coronavirus disease 2019). Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, exerts direct cardioprotective and nephroprotective effects. DARE-19 (Dapagliflozin in Respiratory Failure in Patients With COVID-19), an ongoing clinical trial, is designed to investigate the impact of dapagliflozin on COVID-19 progression. This article discusses the potential favorable impact of dapagliflozin on COVID-19 and its complications.
year | journal | country | edition | language |
---|---|---|---|---|
2021-07-01 | Journal of cardiovascular pharmacology |